---
schema_version: "secwatch.filing_event.v1"
accession: "0001520138-26-000312"
form_type: "8-K"
ticker: "BIVI"
cik: "0001580149"
company_name: "BIOVIE INC."
filed_at: "2026-08-06T11:35:24+00:00"
generated_at: "2026-08-06T11:40:18.106864+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# BioVie Phase 2 SUNRISE-PD trial of bezisterim shows statistically significant improvements vs placebo

## Summary
- Statistically significant improvements on MDS-UPDRS Parts I, II, III and composite EPNIC-15 (p=0.0006).
- Bezisterim improved biomarkers of neuroinflammation and systemic inflammation; composite neuroinflammation measure p=0.0018.
- 283 of 380 proteins shifted toward lower inflammatory burden (binomial p=3.2e-22).
- Bezisterim well-tolerated; adverse events 39.3% vs 51.7% placebo, no severe/serious AEs.
- Conference call scheduled for Aug 12, 2026 to discuss results.

## SEC filing metadata
- accession: 0001520138-26-000312
- form_type: 8-K
- ticker: BIVI
- cik: 0001580149
- company_name: BIOVIE INC.
- filed_at: 2026-08-06T11:35:24+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1580149/000152013826000312/0001520138-26-000312-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1580149/000152013826000312/bivi-20260806_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001520138-26-000312
- JSON: https://secwatch.observer/filing/0001520138-26-000312.json
- Plain text: https://secwatch.observer/filing/0001520138-26-000312.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.